← Back to Portfolio
Jasper
Jasper Therapeutics is focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. In 2025, Jasper reported Phase 1/2 data from the BEACON study of briquilimab in chronic spontaneous urticaria (CSU). Jasper was founded out of Stanford and JSP-191 was invented and developed at Amgen. In May 2021 the company listed on Nasdaq with the ticker JSPR.